Zenas BioPharma, Inc. (ZBIO)
(Delayed Data from NSDQ)
$14.80 USD
-0.90 (-5.73%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $14.82 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ZBIO 14.80 -0.90(-5.73%)
Will ZBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ZBIO
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Sixteen new option listings on July 23rd
ZBIO Crosses Above Key Moving Average Level
Zenas BioPharma assumed with an Overweight at Morgan Stanley
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZBIO Stock News